PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 20, 2026American Journal of Respiratory and Critical Care Medicine

A32-09 Beclometasone/Formoterol (BDP/FF) Is Non-inferior to Budesonide/Formoterol (BUD/FF) as Maintenance and Reliever Therapy (MART) and Reduces Inhaler-related GHG Emissions in Adult Asthma

View Full Paper
Ask AI
Bookmark
Share

Authors

DPD B PriceCJC R JenkinsSRS Ramakrishnan

Discussion

Loading...

Member takes

Overview

Randomized trial compares inhaler therapies in adults with asthma, suggesting reduced environmental impact.

Key Points

  • This research aims to evaluate the non-inferiority of BDP/FF-MART compared to BUD/FF-MART for asthma management and its impact on carbon emissions.
  • Historical cohort study using the UK Optimum Patient Care Research Database
  • Included adults with asthma who initiated BDP/FF-MART or BUD/FF-MART between July 2012 and November 2024
  • Utilized negative binomial regression for exacerbations and logistic regression for asthma control analysis
  • BDP/FF-MART was non-inferior to BUD/FF-MART for exacerbations (IRR: 0.98 [95% CI: 0.93, 1.04])
  • Asthma control for BDP/FF-MART also showed non-inferiority (OR: 0.92 [95% CI: 0.88, 0.96])
  • Mean carbon footprint from inhalers decreased from 87 kg to 85 kg CO2 equivalent after using BDP/FF-MART

Cite This Study

Price et al. (2026) studied this question.

synapsesocial.com/papers/6a0d5122f03e14405aa9d7e9https://doi.org/10.1093/ajrccm/aamag162.304
View Full Paper
Ask AI
Bookmark
Share